57 83

Cited 3 times in

Soluble CD93 in Serum as a Marker of Allergic Inflammation

Authors
 Hye Jung Park  ;  Heejae Han  ;  Sang Chul Lee  ;  Young Woong Son  ;  Da Woon Sim  ;  Kyung Hee Park  ;  Yoon Hee Park  ;  Kyoung Yong Jeong  ;  Jung-Won Park  ;  Jae-Hyun Lee 
Citation
 Yonsei Medical Journal, Vol.58(3) : 598-603, 2017 
Journal Title
 Yonsei Medical Journal 
ISSN
 0513-5796 
Issue Date
2017
MeSH
Adult ; Asthma/blood* ; Asthma/diagnosis ; Asthma/immunology ; Biomarkers/blood ; Case-Control Studies ; Chronic Disease ; Cross-Sectional Studies ; Female ; Humans ; Inflammation/blood ; Inflammation/diagnosis ; Membrane Glycoproteins/blood* ; Membrane Glycoproteins/metabolism ; Middle Aged ; Receptors, Complement/blood* ; Receptors, Complement/metabolism ; Rhinitis, Allergic/blood* ; Rhinitis, Allergic/immunology ; Urticaria/blood* ; Urticaria/diagnosis ; Urticaria/immunology ; Young Adult
Keywords
Allergy ; asthma ; biomarker ; inhaled corticosteroid ; soluble CD93
Abstract
PURPOSE: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. MATERIALS AND METHODS: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. RESULTS: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153.1±58.4) were significantly higher than in patients without AR (132.2±49.0) or with stable AR (122.3±42.1). Serum sCD93 levels in exacerbated CSU (169.5±42.8) were also significantly higher than those in non-CSU (132.4±51.6) and stable CSU (122.8±36.2). This trend was also seen in BA. Serum levels in patients with ICS-naïve BA (161.4±53.1) were significantly higher than those in healthy controls without BA (112.2±30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2±20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naïve patients with BA (195.1±72.7) decreased after ICS use for 4 weeks (134.4±42.8) and 8 weeks (100.7±13.4), serially. CONCLUSION: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naïve patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation.
Files in This Item:
T201703235.pdf Download
DOI
10.3349/ymj.2017.58.3.598
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Institute of Allergy (알레르기연구소) > 1. Journal Papers
Yonsei Authors
Park, Kyung Hee(박경희) ORCID logo https://orcid.org/0000-0003-3605-5364
Park, Jung Won(박중원) ORCID logo https://orcid.org/0000-0003-0249-8749
Park, Hye Jung(박혜정) ORCID logo https://orcid.org/0000-0002-1862-1003
Son, Young Woong(손영웅)
Sim, Da Woon(심다운)
Lee, Sang Chul(이상철)
Lee, Jae Hyun(이재현) ORCID logo https://orcid.org/0000-0002-0760-0071
Jeong, Kyoung Yong(정경용) ORCID logo https://orcid.org/0000-0001-9887-1426
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160763
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse